Vantage Data Centers to Continue Deploying Renewable Generator Fuel, Plans Rollout in Additional Markets in 2023
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced the continued deployment of hydrotreated vegetable oil (HVO), a renewable fuel to replace conventional diesel fuel in generators. The company will roll out HVO in several of its largest markets in North America and EMEA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913529341/en/
Vantage Data Centers continues rollout of HVO in several of its largest markets, including its Cardiff campus pictured here. (Photo: Business Wire)
HVO is 100% biodegradable and non-toxic, offering a more sustainable fuel option while delivering the same level of functionality as traditional diesel. Repurposing waste oils like vegetable oil to create sustainable fuels significantly reduces the embodied carbon due to the cleaner sourcing and creation process. Leveraging HVO offers an actionable opportunity for Vantage and other data center operators to take a positive step toward reducing carbon emissions.
Initially deployed as a pilot at Vantage’s Cardiff, Wales campus in 2022, the company’s deployment of HVO as an alternative to diesel fuel yielded progress toward its carbon goals without the need for new or updated infrastructure. Given the success of the pilot, Vantage officially implemented HVO at its newest facility, CWL13, on the Cardiff campus and is currently working to deploy the renewable fuel throughout the rest of the campus. In addition, Vantage will deploy HVO in one of its North American flagship markets, Santa Clara, California, by the end of the year. Vantage is planning deployments in additional markets subject to fuel availability.
“Making the switch to renewable diesel is one of the many ways we are reducing the carbon emissions of our operations. Reaching net zero by 2030 is an incredibly ambitious goal that will require us to implement a wide variety of solutions. Our focus is on maintaining reliability and affordability while achieving emissions reductions,” said Amanda Abell, senior director of sustainability at Vantage. “We look forward to continuing the rollout of HVO at our campuses across North America and EMEA, where available, in addition to the other programs we have in place to reach our sustainability targets.”
The broad launch of hydrotreated vegetable oil comes as the company progresses toward its sustainability goals. The use of renewable diesel fuels significantly reduces the embodied carbon of the fuel consumed in diesel generators, which helps to reduce Scope 3 emissions associated with the company’s supply chain. According to fuel suppliers, the use of HVO reduces the lifecycle carbon emissions by 65-90% compared to conventional diesel.
In 2022, Vantage partnered with the Data Center Coalition (DCC) and its members to lead a technical working group focused on driving market support for HVO as availability and costs vary by geography. Based in the Northern Virginia area, where HVO prices are approximately 95 percent higher than diesel fuel, DCC seeks to influence the supply chain and stakeholders to unlock increased availability.
“Vantage is working with industry through the Data Center Coalition to accelerate the viability and use of renewable diesel fuels,” said Mark Freeman, vice president, global marketing and public policy at Vantage and Data Center Coalition board member. “By collaborating and sharing information with peers, it helps the entire sector move faster. It is our hope that through partnerships we can convince policy makers, stakeholders and supply chains of the HVO benefits and enlist their help in achieving the widespread production and distribution of the renewable fuel in markets that lack reliable, cost-effective and timely access today.”
“There is strong industry interest in transitioning from diesel as quickly as is practical. While there are no ‘silver bullet’ technological solutions available today to replace backup diesel generators at scale, data centers are actively seeking and evaluating alternatives that can provide environmental sustainability benefits and similar reliability, fuel availability, siting flexibility and workplace safety protections,” explained Josh Levi, president of the Data Center Coalition. “We are seeing widespread interest in leveraging hydrotreated vegetable oil as an alternative to conventional diesel. In fact, a recent member survey found that 92 percent of respondents are interested in piloting renewable diesel in the Northern Virginia market within the next one to two years. We’re pleased to see support for this sustainable fuel and will continue to work closely with member companies as we advocate to speed the viability and availability of alternative, reliable sources for backup energy.”
In addition to Vantage’s continued rollout of HVO, the company is also implementing generator run-time reduction measures to eliminate the creation of emissions from the start. By using an optimized staged implementation of testing and maintenance procedures, Vantage anticipates achieving a 25 to 75 percent reduction in fuel consumption and associated emissions. Vantage is also installing active emissions control systems known as Selective Catalytic Reductions (SCRs) on generators in select markets. SCRs reduce nitrogen oxide emitted from the company’s diesel generators by up to 90%. SCRs are already installed at many facilities across Vantage’s Warsaw, Berlin, Frankfurt and California campuses with additional installations planned for the future.
For more information about Vantage’s sustainability program and priorities, download the 2022 ESG report here.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit http://www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913529341/en/
Contact information
Press Contacts
Mark Freeman
Vantage Data Centers
mfreeman@vantage-dc.com
+1-202-680-4243
Robin Bectel
REQ for Vantage Data Centers
vdc@req.co
+1-202-936-6335
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
